Literature DB >> 17679672

The neuroprotective effects of caffeine: a prospective population study (the Three City Study).

K Ritchie1, I Carrière, A de Mendonca, F Portet, J F Dartigues, O Rouaud, P Barberger-Gateau, M L Ancelin.   

Abstract

OBJECTIVE: To examine the association between caffeine intake, cognitive decline, and incident dementia in a community-based sample of subjects aged 65 years and over.
METHODS: Participants were 4,197 women and 2,820 men from a population-based cohort recruited from three French cities. Cognitive performance, clinical diagnosis of dementia, and caffeine consumption were evaluated at baseline and at 2 and 4 year follow-up.
RESULTS: Caffeine consumption is associated with a wide range of sociodemographic, lifestyle, and clinical variables which may also affect cognitive decline. Multivariate mixed models and multivariate adjusted logistic regression indicated that women with high rates of caffeine consumption (over three cups per day) showed less decline in verbal retrieval (OR = 0.67, CI = 0.53, 0.85), and to a lesser extent in visuospatial memory (OR = 0.82, CI = 0.65, 1.03) over 4 years than women consuming one cup or less. The protective effect of caffeine was observed to increase with age (OR = 0.73, CI = 0.53, 1.02 in the age range 65 to 74; OR = 0.3, CI = 0.14, 0.63 in the range 80+). No relation was found between caffeine intake and cognitive decline in men. Caffeine consumption did not reduce dementia risk over 4 years.
CONCLUSIONS: The psychostimulant properties of caffeine appear to reduce cognitive decline in women without dementia, especially at higher ages. Although no impact is observed on dementia incidence, further studies are required to ascertain whether caffeine may nonetheless be of potential use in prolonging the period of mild cognitive impairment in women prior to a diagnosis of dementia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17679672     DOI: 10.1212/01.wnl.0000266670.35219.0c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  89 in total

1.  Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease.

Authors:  Hisham Qosa; Alaa H Abuznait; Ronald A Hill; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.

Authors:  Annalisa Pinna
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 3.  Beneficial and detrimental role of adenosine signaling in diseases and therapy.

Authors:  Hong Liu; Yang Xia
Journal:  J Appl Physiol (1985)       Date:  2015-08-27

Review 4.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

Review 5.  Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.

Authors:  Will C McClatchey; Gail B Mahady; Bradley C Bennett; Laura Shiels; Valentina Savo
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

6.  Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum.

Authors:  Xuesong Chen; Xun Lan; Ian Roche; Rugao Liu; Jonathan D Geiger
Journal:  J Neurochem       Date:  2008-09-20       Impact factor: 5.372

7.  Differential Behavioral and Biochemical Responses to Caffeine in Male and Female Rats from a Validated Model of Attention Deficit and Hyperactivity Disorder.

Authors:  Fernanda Nunes; Daniela Pochmann; Amanda Staldoni Almeida; Daniela Melo Marques; Lisiane de Oliveira Porciúncula
Journal:  Mol Neurobiol       Date:  2018-03-20       Impact factor: 5.590

8.  Caffeine and cognitive decline in elderly women at high vascular risk.

Authors:  Marie-Noël Vercambre; Claudine Berr; Karen Ritchie; Jae H Kang
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation.

Authors:  Mahmoud L Soliman; Jonathan D Geiger; Xuesong Chen
Journal:  J Neuroimmune Pharmacol       Date:  2016-09-15       Impact factor: 4.147

Review 10.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.